Inclusion Criteria:

- Patient must have confirmed locally advanced or metastatic solid tumors that have
failed to respond to standard therapy, have gotten worse or have come back after
existing therapy

- Has adequate organ function

- Is ECOG Performance Scale 0-1

- Has a negative urine pregnancy test if patient is female

- Is able to swallow capsules and has no surgical or bodily condition that will prevent
the patient from swallowing and absorbing oral medications on an ongoing basis

Exclusion Criteria:

- Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4
weeks of starting the study and has not recovered from adverse events caused by the
treatment

- Is currently participating or has participated in a study with an investigational
compound or device within 28 days

- Has a primary central nervous system tumor

- Has a history or current evidence of heart disease, slow heart rate or untreated high
blood pressure

- Is a known diabetic who is taking insulin or oral antidiabetic therapy

- Is pregnant or breastfeeding or planning to become pregnant during the study

- Is positive HIV antibody, HBs antigen or HCV antibody